我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 UCB Holdings, Inc.
相关临床试验
26
20 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2008
进行中（未招募）
20
76.9%
已完成
4
15.4%
终止
2
7.7%
暂无批准数据
- GlycoEra AG has appointed Petra Duda, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its precision immune degrader pipeline. - Dr. Duda brings over 20 years of experience in clinical development and regulatory strategy, with expertise in immune-mediated and rare diseases. - She will oversee advancement of GlycoEra's lead IgG4 degrader program GE8820 for autoimmune diseases including pemphigus, MuSK MG, and primary membranous nephropathy. - The appointment comes as GlycoEra advances its glyco-engineering platform designed to degrade disease-causing proteins without generalized immunosuppression.
